Updates on risk of uterine perforation with intrauterine devices

Bayer is informing healthcare professionals of recently available safety information from a large prospective, comparative, non-interventional cohort study using intra-uterine devices. The “European Active Surveillance Study for Intrauterine Devices” (EURAS-IUD) study showed that there is a higher risk of uterine perforation in breastfeeding women and also in women who are up to 36 weeks post-partum at the time of insertion for both levonorgestrel-intrauterine system (LNG-IUS) and copper IUDs (Cu IUDs). Healthcare professionals are recommended to take this information into consideration when selecting IUDs for use in patients who are less than 36 weeks post-partum or breastfeeding at the time of insertion.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.